1
|
Sano M, Taibi E, Alì M, Chiarenza M, Clementi S, Caruso M, Aiello R. Efficacy and Safety of Trastuzumab in Small HER2 Positive Tumors. A Single Institution Experience. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32837-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
2
|
Scandurra G, Aiello RA, Taibi E, Sanò MV, Ali M, Fallica G, Chiarenza M, Mazzola A, Di Marco R, Clementi S, Di Leo MGV, Miano E, Caruso M. Different outcomes of cardiologic safety of trastuzumab in adjuvant or metastatic setting in patients with breast cancer: A single institution experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Carillio G, Aiello R, Mazzola A, Ali' M, Scandurra G, Taibi E, Chiarenza M, Fallica G, Caruso F, Caruso M. Use of trastuzumab associated with cisplatin and vinorelbine followed by docetaxel as a neoadjuvant regimen for patients with HER2-positive breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Scandurra G, Taibi E, Aiello RA, Chiarenza M, Mazzola A, Vita Sano M, Miano E, Fallica G, Caruso M. After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting—A single-institution experience. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1136] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Carillio G, Aiello R, Alì M, Mazzola A, Scandurra G, Taibi E, Chiarenza M, Fallica G, Caruso F, Caruso M. Neoadjuvant trastuzumab in a sequential nonanthracycline-based regimen for patients with stage II-III breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e11559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11559 Background: Recently, some studies have demonstrated benefit from adding trastuzumab to neoadjuvant anthracycline-containing chemotherapy for HER2-positive breast cancer patients. However, trastuzumab can increase cardiotoxicity, particularly when combined with anthracyclines. This represents a relevant issue for patients who usually need to receive radiotherapy or further systemic treatment. Methods: In the late 2007 we started a phase II study for testing activity and safety of neoadjuvant trastuzumab in association with sequential chemotherapy, based on favourable in vitro combination index, proven efficacy, and moderate cardiotoxicity. Weekly trastuzumab for 18 weeks was combined with cisplatin 80 mg/m2 on day 1 and vinorelbine 25 mg/m2 on days 1+8 q3w for 3 courses, followed by docetaxel 100 mg/m2 q3w for further 3 courses. Peg- filgrastim was administered to prevent neutropenia. Adjuvant trastuzumab q3w was planned for one year. Eligible patients had stage II-III core-biopsied breast carcinoma with overexpressed or amplified HER2/neu. Adequate cardiac function with LVEF ≥ 50% was required for trastuzumab administration. Primary end-point was pathologic complete responses (pCR) rate. The study is registered on the European Clinical Trials Database. Results: Among 17 enrolled patients, 15 were evaluable for primary end-point. Median age was 50 years (range 23–70), stage II and III breast cancer in 4 and 13 patients, respectively, with 4 cases of stage IIIB (2 T4b and 2 T4d), and 2 women with synchronous bilateral cancer. Neoadjuvant regimen yielded 6/15 pCR (40%). Only 3/12 patients treated with lymphadenectomy due to initial clinically suspected axillary nodes presented pN+, but none of them had more than 3 positive nodes. In two cases we observed a total pCR, involving both primary tumor and axillary nodes. Treatment was safe, with only 2 events of short G4 non febrile neutropenia on 97 chemotherapy cycles. Alopecia was moderate at the end of treatment, without any case of complete hair loss. No significant cardiac dysfunction was recorded during the neoadjuvant therapy. Conclusions: The present sequential non anthracycline-based chemotherapy associated with weekly trastuzumab showed promising results in neoadjuvant setting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Carillio
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - R. Aiello
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - M. Alì
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - A. Mazzola
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - G. Scandurra
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - E. Taibi
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - M. Chiarenza
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - G. Fallica
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - F. Caruso
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| | - M. Caruso
- Humanitas Centro Catanese Di Oncologia, Catania, Italy
| |
Collapse
|
6
|
Carillio G, Scandurra G, Aiello R, Taibi E, Mazzola A, Alì M, Bagnato S, Fallica G, Chiarenza M, Caruso M. Fulvestrant in metastatic breast cancer: Safety, efficacy, and role as mainteinance therapy for heavily pretreated patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Carillio G, Alì M, Mazzola A, Bagnato S, Todaro A, D’Agostino A, Girlando A, Aiello R, Fallica G, Chiarenza M, Caruso M. Association of weekly gemcitabine to conformal radiotherapy as organ-sparing strategy in locally advanced or relapsed bladder cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15570 Background: Radical surgery is considered the only curative option for locally advanced or relapsed bladder cancer. However, the uncertain prognosis of disease and the poor quality of life due to lack of bladder reservoir require further investigation on possible therapeutic approaches. Methods: This trial has been designed for testing safety and activity of dose-escalating gemcitabine associated to concomitant conformal radiotherapy for locally advanced or relapsed bladder cancer. Patients received radiotherapy at 2 Gy per day to reach a total dose of 60 Gy over 6 weeks. Gemcitabine was administered once-a-week as one-hour IV infusion before starting the radiation treatment. The first explored dose of drug was 300 mg/m2 and the escalation was planned through a Fibonacci modified method by subsequent increases of 100 mg/m2 until definition of the dose-limiting toxicity (DLT). The recommended dose for future phase II study was one level inferior to the reached maximum tolerated dose (MTD). Results: Eighteen patients with median age of 72 years entered the study, half of whom affected by locally advanced tumours, the remainders by recurrence after conservative surgery. The majority of the latter initially had pT2 (UICC staging) muscle invasive transitional cell carcinoma. Twelve patients were treated with weekly gemcitabine at 300 mg/m2 without appearance of any DLT. Among the first 3 patients receiving the dose level of 400 mg/m2, one patient had grade 4 neutropenia. Further 3 patients were enrolled for testing the above dose level, but one of them experienced bowel perforation, therefore the established MTD was 400 mg/m2. The recommended dose of weekly gemcitabine was 300 mg/m2. Effectively, we could observe 11 (61%) pathological complete responses (pCR) confirmed by bladder mapping two months after treatment completion. Nine pCR (82%) occurred in the patients with locally advanced therapy-naïve bladder cancer. Patients with conserved bladders had excellent function, without hematuria, urgency or incontinence. Conclusions: The association of weekly gemcitabine to conformal radiotherapy provides a new alternative to radical surgery approach and strongly supports the organ-sparing strategy for locally advanced bladder cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Carillio
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - M. Alì
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - A. Mazzola
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - S. Bagnato
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - A. Todaro
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - A. D’Agostino
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - A. Girlando
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - R. Aiello
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - G. Fallica
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - M. Chiarenza
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| | - M. Caruso
- Humanitas Centro Catanese di Oncologia, Catania, Italy
| |
Collapse
|
8
|
Pafumi C, Farina M, Bandiera S, Cavallaro A, Pernicone G, Russo A, Iemmola A, Chiarenza M, Leonardi I, Calogero AE, Calcagno A, Cianci A. Differences in umbilical cord blood units collected during cesarean section, before or after the delivery of the placenta. Gynecol Obstet Invest 2003; 54:73-7. [PMID: 12566747 DOI: 10.1159/000067714] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2001] [Indexed: 11/19/2022]
Abstract
Umbilical cord blood is largely employed as an alternative source of stem cells in the treatment of hemato-oncological diseases. Current results show that the success rate of purified umbilical cord blood engraftment is comparable to that obtained using bone marrow, and it is directly related to the number of pluripotent stem cells transplanted. The technique of fetal blood collection varies among different umbilical cord blood banks. Many authors collect umbilical cord blood during vaginal delivery, after placental detachment, while others collect it while the placenta is still within the uterus. In a previous randomized trial, we showed a greater collection of umbilical cord blood before placental detachment during vaginal delivery. The present study was performed to determine whether umbilical cord blood collection before placental detachment (group A) during cesarean section is superior to that after placental delivery (group B) puncturing the umbilical vein once and using a closed bag system. To accomplish this, 47 pregnant women subjected to cesarean section were enrolled in the study. Twenty-one of them were allocated to group A, while the remaining 26 formed group B. The volume of umbilical cord blood collected from the patients of group A was greater than that collected from patients of group B. The cord blood volume collected was 90.7 +/- 6.0 versus 60.9 +/- 13.7 ml; the cord blood nucleated cell number was 10.1 +/- 1.2 x 10(8) vs. 7.1 +/- 0.8 x 10(8); and the mean cord blood CD34+ cell number was 20.0 +/- 6.0 x 10(5) vs. 16.4 +/- 2.4 x 10(5), respectively.
Collapse
Affiliation(s)
- C Pafumi
- Department of Microbiological and Gynecological Sciences, Section of Endocrinology, Andrology and Internal Medicine, University of Catania, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Pafumi C, Ciotta L, Farina M, Bosco P, Chiarenza M, Pernicone G, Calcagno A, Evola F, Cavallaro A, Iemmola A, Cianci A. Evaluation of bone mass in young amenorrheic women with anorexia nervosa. Minerva Ginecol 2002; 54:487-91. [PMID: 12432331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
BACKGROUND In the last 10 years an impressive increase in the frequency of food disorders (bulimia and anorexia) in teenagers has been recorded. Food disorders, present especially in girls, (part of more complex relational-familiar disorders) cause progressive repercussions on the general endocrine structure and in particular on the reproductive system of the subject. The most visible effect of this endocrine perturbation is the block of the ovarian function with secondary amenorrhoea and low levels of gonadotropins and estrogens due to the food disorder. In fact the qualitative and quantitative food deficit is responsible for the interruption of the normal hypothalamic and pituitary pulses regulating the correct monthly process of follicular growth. As in the physiological postmenopausal period, very low plasma levels of 17-b-estradiol (<30 pg/ml) can start the bone resorption with bone loss and/or osteoporosis related to the amount and the time of exposure to low levels of estrogens. OBJECTIVES in our study we evaluate the influence of anorexia and amenorrhoea on bone mineral density. METHODS We evaluate bone mineral density (BMD) with computerised bone mineralometry (MOC), a dual-energy-X-Ray (DEXA), in 18 women with anorexia nervosa and weight loss, 9-12 months amenorrhoea and with low plasma levels of 17-b-estradiol. The BMD was measured at the lumbar spine (L2-L4) and on total body in all subjects enrolled for this study. RESULTS All the patients showed a decrease on the lumbar BMD with bone loss (49%) or osteoporosis (51%). On the other side the values of total body BMD were around the normal levels (86%) or showed bone loss (14%). CONCLUSIONS Our data support the hypothesis that lower estrogenic levels associated with anorexia nervosa have an impact on BMD, especially at lumbar level, with early incidence for quantitative and qualitative lower food intake.
Collapse
Affiliation(s)
- C Pafumi
- Department of Microbiological and Gynecological Sciences, University of Catania, Catania, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Pafumi C, Chiarenza M, Russo A, Farina M, Pernicone G, Bandiera S, Giardina P, Cavallaro A, Leonardi I, Calogero AE, Cianci A. Collection of umbilical cord in cesarean section and vaginal delivery. Ann Saudi Med 2002; 22:408-10. [PMID: 17146278 DOI: 10.5144/0256-4947.2002.408a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
11
|
Pafumi C, Bosco P, Cavallaro A, Farina M, Leonardi I, Pernicone G, Bandiera S, Russo A, Giardina P, Chiarenza M, Calogero AE. Two CD34+ stem cells from umbilical cord blood enrichment methods. Pediatr Hematol Oncol 2002; 19:239-45. [PMID: 12051590 DOI: 10.1080/08880010252899406] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The authors describe the relation between clamping time and blood volume collected, and two enrichment systems of CD34+ stem cells from umbilical cord blood, to determine an excellent recovery with high proliferate ability and bone marrow reconstitution. After an obstetrician-based cord blood collection, the purification of stem cells was performed either with a combination of monoclonal antibodies (negative selections) using the Stem Sep method, or with a positive cells selection thanks to their surface CD34 antigens, using the Mini Macs system. An excellent recovery of hematopoietic progenitors, burst-forming unit erythroid, colony-forming unit granulocyte and macrophage, and colony-forming unit granulocyte, erythroid, monocyte, and macrophage, inversely related to the rising of clamping time, was performed with the Mini Macs system (54% of colonies, with a 90% purity), while with Stem Sep method, hematopoietic progenitor recovery was 35% (with an 80% purity). By applying early clamping of the umbilical cord blood a greater number of CD34+ cells was obtained and their clonogenic activity increased with enrichment. This is particularly useful, considering that the number of CD34+ stem cells contained in a unit of placental blood is enough for transplanting to a child, but not for an adult engraftment. Thus, using this method, a larger number of CD34+ stem cells can be obtained, which increases the possibility to reduce graft versus host disease also in adult patients, producing survival rates similar to the ones obtained with transplantation of bone marrow from unrelated donors.
Collapse
Affiliation(s)
- C Pafumi
- Institute of Obstetrics and Gynaecology, University of Catania, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Pafumi C, Ciotta L, Farina M, Maggi I, Intelisano G, Fiorito A, Chiarenza M, Cavallaro A, Pernicone A, Bosco P, Russo A, Bandiera S, Giardina P, Cianci A. Influence of sport and low animal saturated fats intake diet on lipid dismetabolisms in postmenopausal women. Minerva Ginecol 2002; 54:279-85. [PMID: 12063444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
BACKGROUND An important aetiopathogenetic factor leading to menopausal age pathologies (such as hypertension, diabetes, cardiovascular diseases and so on) is certainly represented by the worsening of lipid dismetabolism. This condition is generally characterized by an increase in total mean cholesterol levels, LDL-cholesterol (low density lipoprotein-cholesterol), VLDL-cholesterol (very low density lipoprotein-cholesterol), triglycerides, with reduction of HDL-cholesterol (high density lipoprotein-cholesterol) mean levels. All these metabolic modifications are triggered or increased by the hypoestrogenemia typical of postmenopausal age. The aim of our study was to evaluate the influence on postmenopausal women's lipid metabolism of a low contribution of animal saturated fat diets, associated with physical training. METHODS We enrolled in our study 36 mild hypercholesterolemic postmenopausal women (non smokers and not complaining of hypertension and diabetes) and we put them through aerobic training, consisting of 1 hour of a light continuous run, repeated 4 times per week. The final control of their metabolic status and of their lipid order was executed after 6 months, but during this period, all the women were observed bi-weekly or monthly, to assure a high uniform compliance in the group. None of the women enrolled took specific drugs for the lipid metabolism during the study. RESULTS After 6 months from the beginning of the diet, with associated physical training, an important weight loss was observed. Increases of HDL-cholesterol mean levels (p<0.05) associated with a decrease of total cholesterol mean levels (p<0.05) were reported in all the subject examined. A statistically non-significant decrease in LDL and VLDL cholesterol mean levels was also noticed. CONCLUSIONS A mild lipid dysmetabolism in postmenopause may be corrected advantageously by an opportune diet associated with moderate, but constant, physical training.
Collapse
Affiliation(s)
- C Pafumi
- Department of Microbiology and Obstetrical Science, University of Catania, Catania, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Gebbia V, Caruso M, Valenza R, Testa A, Cannata G, Verderame F, Cipolla C, Curto G, Oliveri D, Chiarenza M. Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res 1994; 14:1247-9. [PMID: 8067691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Thirty consecutive patients with stage IIIB-IV non small cell lung cancer were treated with a combination of cisplatin 80 mg/m2 on day 1 plus vinorelbine 25-30 mg/m2 on days 1, 8. This cycle was repeated every 3 weeks. The overall response rate was 46%, with 1 patient showing a complete response and 13 patients (43%) a partial response with a mean duration of 8.4+ months. Six patients had a stabilization and 10 progressed. The main toxicities were represented by myelosuppression and nausea/vomiting. Grade 3 leukopenia was seen in 33% of cases, grade 2 thrombocytopenia in 12%, and phlebitis in the injection vein in 16%. Mild constipation was also recorded. The combination of cisplatin plus vinorelbine is quite effective in advanced non small cell carcinoma of the lung, and may be safely given on an outpatient basis.
Collapse
Affiliation(s)
- V Gebbia
- Service of Chemotherapy, Institute of Pharmacology, University of Palermo, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Battacchi MW, Chiarenza M, Giovanelli G, Tampieri P. Character impulsivity in terms of speech and motor behaviour. Psychol Forsch 1968; 31:275-86. [PMID: 5702085 DOI: 10.1007/bf00422715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|